Millennium Management’s Relmada Therapeutics RLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-75,000
Closed -$243K – 6392
2024
Q3
$243K Buy
+75,000
New +$243K ﹤0.01% 5325
2022
Q4
– Sell
-124,900
Closed -$4.62M – 6967
2022
Q3
$4.62M Buy
124,900
+35,600
+40% +$986K ﹤0.01% 2968
2022
Q2
$1.7M Buy
+89,300
New +$1.95M ﹤0.01% 3874
2022
Q1
– Sell
-50,000
Closed -$1.13M – 7391
2021
Q4
$1.13M Buy
+50,000
New +$1.11M ﹤0.01% 4305

Other funds holding RLMD

Millennium Management's RLMD Position: Q3 2026 in Review

Millennium Management increased its Relmada Therapeutics (RLMD) stake by 42% in Q3 2026, buying an estimated $4.83M and bringing the position to 3,345,573 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Millennium Management first reported a position in RLMD in Q4 2019 and has held it in 23 quarters since. The position peaked at $27.2M in Q1 2026. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • Millennium Management held 3,345,573 shares of Relmada Therapeutics worth $12.6M as of Q3 2026.
  • Millennium Management bought 983,746 Relmada Therapeutics shares in Q3 2026, an estimated $4.83M.
  • Relmada Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #2064 holding.
  • Millennium Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Millennium Management's Relmada Therapeutics position peaked at $27.2M in Q1 2026.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.